TCR² Therapeutics to Participate in Two Upcoming Conferences in February
Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will participate in a fireside chat at the SVB Leerink9th Annual Global Healthcare Conference on February 25, 2020at 1:00pm ETin New York, NY Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, will present an update on company progress during the panel “Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors” at the Immuno-Oncology 360° Conference on February 27, 2020at 10:40am ETin New York, NY
A live webcast of the
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. For more information about TCR2, please visit www.tcr2.com.
Investor and Media Contact:
Director, Investor Relations and Corporate Communications
Source: TCR2 Therapeutics